Lifesci Capital Has Negative Estimate for DFTX Q2 Earnings

Definium Therapeutics, Inc. (NASDAQ:DFTX) – Analysts at Lifesci Capital decreased their Q2 2026 EPS estimates for Definium Therapeutics in a research note issued on Friday, May 8th. Lifesci Capital analyst F. Brisebois now expects that the company will post earnings of ($0.55) per share for the quarter, down from their previous estimate of ($0.50). The consensus estimate for Definium Therapeutics’ current full-year earnings is ($1.97) per share. Lifesci Capital also issued estimates for Definium Therapeutics’ Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.55) EPS and FY2026 earnings at ($2.31) EPS.

Definium Therapeutics (NASDAQ:DFTX) last announced its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.23).

Other analysts have also issued reports about the stock. Jefferies Financial Group assumed coverage on shares of Definium Therapeutics in a research report on Thursday, January 29th. They set a “buy” rating and a $30.00 target price for the company. Royal Bank Of Canada boosted their target price on shares of Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a research report on Friday, January 23rd. Stifel Nicolaus set a $30.00 target price on shares of Definium Therapeutics and gave the company a “buy” rating in a research report on Thursday, April 16th. HC Wainwright boosted their target price on shares of Definium Therapeutics from $55.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Finally, Canaccord Genuity Group set a $38.00 target price on shares of Definium Therapeutics and gave the company a “buy” rating in a research report on Thursday, April 16th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Definium Therapeutics has an average rating of “Buy” and a consensus price target of $37.92.

Definium Therapeutics Stock Performance

Shares of NASDAQ DFTX opened at $21.40 on Tuesday. The firm has a 50 day moving average of $20.15 and a 200 day moving average of $16.17. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $2.13 billion, a price-to-earnings ratio of -8.59 and a beta of 2.37. Definium Therapeutics has a 12-month low of $6.16 and a 12-month high of $26.25.

Hedge Funds Weigh In On Definium Therapeutics

Large investors have recently added to or reduced their stakes in the company. BIT Capital GmbH purchased a new position in Definium Therapeutics during the third quarter valued at approximately $26,000. Fifth Third Bancorp boosted its position in shares of Definium Therapeutics by 5,593.2% during the third quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock worth $40,000 after acquiring an additional 3,300 shares during the last quarter. Russell Investments Group Ltd. boosted its position in shares of Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after acquiring an additional 2,003 shares during the last quarter. BNP Paribas Financial Markets boosted its position in shares of Definium Therapeutics by 56.0% during the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after acquiring an additional 3,020 shares during the last quarter. Finally, Flagship Harbor Advisors LLC bought a new position in shares of Definium Therapeutics during the fourth quarter worth $117,000. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.